Patents by Inventor Bruce Randazzo

Bruce Randazzo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of Treating Psoriasis in Pediatric Subjects with Anti-IL12/IL23 Antibody
    Publication number: 20240101662
    Abstract: Anti-IL-12/IL-23p40 antibodies, such as ustekinumab, are used in methods and compositions for safe and effective treatment of psoriasis, particularly moderate to severe chronic plaque psoriasis, in pediatric patients. The methods and compositions address a clear unmet medical need in this patient population.
    Type: Application
    Filed: November 20, 2023
    Publication date: March 28, 2024
    Inventors: Ming-Chun Hsu, Shu Li, Bruce Randazzo, Kun Song, Yaowei Zhu
  • TREATMENT OF HIDRADENITIS SUPPURATIVA
    Publication number: 20230235042
    Abstract: Hidradenitis suppurativa can be treated by administering a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds IL-1?.
    Type: Application
    Filed: April 16, 2021
    Publication date: July 27, 2023
    Inventors: Yanli ZHUANG, Bhaskar SRIVASTAVA, Karen KEEFE, Swaroopa PARATKAR, Bruce RANDAZZO, Emesto MUNOZ, John SIMARD
  • Method of Treating Psoriasis in Pediatric Subjects with Anti-IL12/IL23 Antibody
    Publication number: 20230014839
    Abstract: Anti-IL-12/IL-23p40 antibodies, such as ustekinumab, are used in methods and compositions for safe and effective treatment of psoriasis, particularly moderate to severe chronic plaque psoriasis, in pediatric patients. The methods and compositions address a clear unmet medical need in this patient population.
    Type: Application
    Filed: September 13, 2022
    Publication date: January 19, 2023
    Inventors: Ming-Chun Hsu, Shu Li, Bruce Randazzo, Kun Song, Yaowei Zhu
  • Safe and effective method of treating psoriasis with anti-IL-23 specific antibody
    Patent number: 11548941
    Abstract: A method of treating psoriasis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a clinically proven safe and clinically proven effective amount and the patient achieves PASI90, PASI100 or IGA 0 or 1 score as measured 16, 24, 32, 40 and 48 weeks after initial treatment and the patient achieves higher efficacy than a patient treated with the secukinumab antibody.
    Type: Grant
    Filed: November 19, 2019
    Date of Patent: January 10, 2023
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Julianty Angsana, Patrick Branigan, Samuel DePrimo, Susan Flavin, Shu Li, Xuejun Liu, Ernesto Munoz, Bruce Randazzo
  • SAFE AND EFFECTIVE METHOD OF TREATING PSORIASIS WITH ANTI-IL-23 SPECIFIC ANTIBODY
    Publication number: 20220289835
    Abstract: A method of treating psoriasis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a clinically proven safe and clinically proven effective amount and the patient achieves PASI90, PASI100 or IGA 0 or 1 score as measured 16, 24, 32, 40 and 48 weeks after initial treatment and the patient achieves higher efficacy than a patient treated with the secukinumab antibody.
    Type: Application
    Filed: May 2, 2022
    Publication date: September 15, 2022
    Inventors: Julianty Angsana, Patrick Branigan, Samuel DePrimo, Susan Flavin, Shu Li, Xeujun Liu, Ernesto Munoz, Bruce Randazzo
  • Method of Treating Psoriasis in Pediatric Subjects with Anti-IL12/IL23 Antibody
    Publication number: 20220073603
    Abstract: Anti-IL-12/IL-23p40 antibodies, such as ustekinumab, are used in methods and compositions for safe and effective treatment of psoriasis, particularly moderate to severe chronic plaque psoriasis, in pediatric patients. The methods and compositions address a clear unmet medical need in this patient population.
    Type: Application
    Filed: July 30, 2021
    Publication date: March 10, 2022
    Inventors: Ming-Chun Hsu, Shu Li, Bruce Randazzo, Kun Song, Yaowei Zhu
  • Safe and Effective Method of Treating Psoriasis with Anti-IL23 Specific Antibody
    Publication number: 20200385454
    Abstract: A method of treating psoriasis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a safe and effective amount and the patient achieves PASI90, PASI100 or IGA 0 or 1 score as measured 16, 24, 32, 40 and 48 weeks after initial treatment.
    Type: Application
    Filed: August 13, 2020
    Publication date: December 10, 2020
    Inventors: Bruce Randazzo, Yasmine Wasfi
  • Method of Treating Psoriasis in Pediatric Subjects with Anti-IL12/IL23 Antibody
    Publication number: 20200331996
    Abstract: Anti-IL-12/IL-23p40 antibodies, such as ustekinumab, are used in methods and compositions for safe and effective treatment of psoriasis, particularly moderate to severe chronic plaque psoriasis, in pediatric patients. The methods and compositions address a clear unmet medical need in this patient population.
    Type: Application
    Filed: March 16, 2020
    Publication date: October 22, 2020
    Inventors: Ming-Chun Hsu, Shu Li, Bruce Randazzo, Kun Song, Yaowei Zhu
  • Safe and Effective Method of Treating Psoriasis with Anti-IL-23 Specific Antibody
    Publication number: 20200157209
    Abstract: A method of treating psoriasis in a patient by administering an IL-23 specific antibody, e.g.
    Type: Application
    Filed: November 19, 2019
    Publication date: May 21, 2020
    Inventors: Julianty Angsana, Patrick Branigan, Samuel DePrimo, Susan Flavin, Shu Li, Xuejun Liu, Ernesto Munoz, Bruce Randazzo
  • Safe and Effective Method of Treating Psoriasis with Anti-IL23 Specific Antibody
    Publication number: 20180094052
    Abstract: A method of treating psoriasis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a safe and effective amount and the patient achieves PASI90, PASI100 or IGA 0 or 1 score as measured 16, 24, 32, 40 and 48 weeks after initial treatment.
    Type: Application
    Filed: September 29, 2017
    Publication date: April 5, 2018
    Inventors: Bruce Randazzo, Yasmine Wasfi
  • TREATMENT OF NON-NEURONAL CANCER USING HSV-1 VARIANTS
    Publication number: 20070292394
    Abstract: A mutant herpes simplex virus which has been modified in the ?34.5 gene such that the gene is non-functional is used to treat a non-neuronal cancer such as a mesothelioma, ovarian carcinoma, bladder cancer or melanoma. Typically, the mutant herpes simplex virus has been modified within the BamHI restriction fragment of the long terminal repeat of the viral genome.
    Type: Application
    Filed: June 19, 2007
    Publication date: December 20, 2007
    Inventors: Susanne Brown, Alasdair Maclean, Nigel Fraser, Bruce Randazzo, Steven Albelda, Larry Kaiser, John Kucharczuk
  • Treatment of cancer using HSV mutant
    Publication number: 20050260169
    Abstract: Use as an anti-cancer agent of a mutant herpes simplex virus wherein the mutant virus comprises a modification in the ?34.5 gene in the long repeat region (RL) such that the ?34.5 gene is a non-functional, manufacture of medicaments and methods of testing cancer in mammals employing HSV mutant.
    Type: Application
    Filed: June 13, 2005
    Publication date: November 24, 2005
    Inventors: Alasdair MacLean, Susanne Brown, Nigel Fraser, Bruce Randazzo
  • Treatment of non-neuronal cancer using HSV-1 variants
    Publication number: 20050226850
    Abstract: A mutant herpes simplex virus which has been modified in the ?34.5 gene such that the gene is non-functional is used to treat a non-neuronal cancer such as a mesothelioma, ovarian carcinoma, bladder cancer or melanoma. Typically, the mutant herpes simplex virus has been modified within the BamHI restriction fragment of the long terminal repeat of the viral genome.
    Type: Application
    Filed: June 8, 2005
    Publication date: October 13, 2005
    Inventors: Susanne Brown, Alasdair MacLean, Nigel Fraser, Bruce Randazzo, Steven Albelda, Larry Kaiser, John Kucharczuk